Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Since the hypofunction of the N-methyl-D-aspartate (NMDA) receptor is known to be involved in the pathophysiology of schizophrenia, the enhancement of NMDA receptor function through glycine modulatory sites is expected to be a useful approach for the treatment of schizophrenia.

Objectives

We investigated the efficacy of a glycine transporter 1 (GlyT1) inhibitor that potentiates NMDA receptor function by increasing synaptic glycine levels in animal models for cognitive dysfunction and negative symptoms, both of which are poorly managed by current antipsychotics.

Results

A newly synthesized GlyT1 inhibitor, 3-chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidin-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide (TASP0315003) significantly improved cognitive deficit induced by MK-801 in the object recognition test in rats. Likewise, TASP0315003 significantly improved MK-801 impaired cognition in the social recognition test in rats and also enhanced social memory in treatment-naïve rats. In addition, repeated phencyclidine (PCP) treatment reduced the social interaction of paired mice, which may reflect negative symptoms such as social withdrawal, and both acute and sub-chronic treatment with TASP0315003 reversed the reduction in social interaction induced by PCP. Moreover, TASP0315003 additionally exhibited an antidepressant effect in the forced swimming test in rats. In contrast, TASP0315003 did not affect spontaneous locomotor activity or rotarod performance and did not induce catalepsy, indicating that TASP0315003 does not cause sedation or motor dysfunction, which is sometimes observed with the use of current antipsychotics.

Conclusions

These results suggest that GlyT1 inhibitors including TASP0315003 may be useful for the treatment of cognitive dysfunction and the negative symptoms of schizophrenia without having undesirable central nervous system side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  • Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E, Pinard E, Knoflach F, Schlotterbeck G, Hainzl D, Wettstein JG (2012) Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 62:1152–1161. doi:10.1016/j.neuropharm.2011.11.008

    Article  CAS  PubMed  Google Scholar 

  • Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 91:47–58. doi:10.1016/j.pbb.2008.06.009

    Article  CAS  PubMed  Google Scholar 

  • Bugarski-Kirola D, Wang A, Abi-Saab D, Blättler T (2014) A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia—results from the CandleLyte study. Eur Neuropsychopharmacol 24:1024–1036. doi:10.1016/j.euroneuro.2014.03.007

    Article  CAS  PubMed  Google Scholar 

  • Chaki S, Hirota S, Funakoshi T, Suzuki Y, Suetake S, Okubo T, Ishii T, Nakazato A, Okuyama S (2003) Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J Pharmacol Exp Ther 304:818–826

    Article  CAS  PubMed  Google Scholar 

  • Coyle JT, Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174:32–38

    Article  CAS  Google Scholar 

  • Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30:1963–1985

    Article  PubMed  Google Scholar 

  • Enomoto T, Noda Y, Nabeshima T (2007) Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 29:291–301

    Article  CAS  PubMed  Google Scholar 

  • Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313:176–190

    Article  CAS  PubMed  Google Scholar 

  • Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 26:119–136

    Article  CAS  PubMed  Google Scholar 

  • Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301–307

    Article  PubMed  Google Scholar 

  • Grimwood S, Moseley AM, Carling RW, Leeson PD, Foster AC (1992) Characterization of the binding of [3H]L-689,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. Mol Pharmacol 41:923–930

    CAS  PubMed  Google Scholar 

  • Gururajan A, Taylor DA, Malone DT (2010) Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav Pharmacol 21:690–709. doi:10.1097/FBP.0b013e32833fa7df

    Article  CAS  PubMed  Google Scholar 

  • Hanson E, Healey K, Wolf D, Kohler C (2010) Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep 12:563–571. doi:10.1007/s11920-010-0148-0

    Article  PubMed  Google Scholar 

  • Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, Aota M, Saita K, Doihara H, Sato Y, Yamaji T, Ni K, Matsuoka N (2012) A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer’s disease. Eur J Pharmacol 685:59–69. doi:10.1016/j.ejphar.2012.04.013

    Article  CAS  PubMed  Google Scholar 

  • Horiguchi M, Huang M, Meltzer HY (2011) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338:605–614. doi:10.1124/jpet.111.180638

    Article  CAS  PubMed  Google Scholar 

  • Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY, Tsai GE (2013) Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 74:734–741. doi:10.1016/j.biopsych.2013.02.020

    Article  CAS  PubMed  Google Scholar 

  • Karasawa J, Hashimoto K, Chaki S (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186:78–83

    Article  CAS  PubMed  Google Scholar 

  • King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC (2004) 5–HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation–an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47:195–204

    Article  CAS  PubMed  Google Scholar 

  • Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214

    Article  CAS  PubMed  Google Scholar 

  • Krystal JH, D’Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215–233

    Article  CAS  Google Scholar 

  • Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–1141. doi:10.1016/j.biopsych.2013.03.026

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE (2005) Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62:1196–1204

    Article  CAS  PubMed  Google Scholar 

  • Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE (2010) A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 13:451–460. doi:10.1017/S1461145709990939

    Article  CAS  PubMed  Google Scholar 

  • Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223–239

    Article  CAS  PubMed  Google Scholar 

  • Loiseau F, Dekeyne A, Millan MJ (2008) Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl) 196:93–104

    Article  CAS  Google Scholar 

  • Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H, Kayukawa Y, Ohta T, Nabeshima T (2001) Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12:11–15

    Article  CAS  PubMed  Google Scholar 

  • Rajagopal L, Massey BW, Huang M, Oyamada Y, Meltzer HY (2014) The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 20:5104–5014

    Article  CAS  PubMed  Google Scholar 

  • Sams-Dodd F (1996) Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7:3–23

    CAS  PubMed  Google Scholar 

  • Schoemaker JH, Jansen WT, Schipper J, Szegedi A (2014) The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol 34:190–198. doi:10.1097/JCP.0000000000000073

    Article  CAS  PubMed  Google Scholar 

  • Shimazaki T, Kaku A, Chaki S (2010) D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl) 209:263–270. doi:10.1007/s00213-010-1794-y

    Article  CAS  Google Scholar 

  • Singer P, Boison D, Möhler H, Feldon J, Yee BK (2007) Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. Behav Neurosci 121:815–825

    Article  PubMed  Google Scholar 

  • Tsai G, Lane HY, Yang P, Chong MY, Lange N (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452–456

    Article  CAS  PubMed  Google Scholar 

  • Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L (2014) Effect of Bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 71:637–646. doi:10.1001/jamapsychiatry.2014.163

    Article  CAS  PubMed  Google Scholar 

  • Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl) 172:375–383

    Article  Google Scholar 

  • Wang D, Noda Y, Zhou Y, Nitta A, Furukawa H, Nabeshima T (2007) Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacology 52:1179–1187

    Article  CAS  PubMed  Google Scholar 

  • Watson DJ, Loiseau F, Ingallinesi M, Millan MJ, Marsden CA, Fone KC (2012) Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 37:770–786. doi:10.1038/npp.2011.254

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Young AB, Snyder SH (1973) Strychnine binding associated with glycine receptors of the central nervous system. Proc Natl Acad Sci U S A 70:2832–2836

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan

    Shigeyuki Chaki, Toshiharu Shimazaki, Jun-ichi Karasawa, Takeshi Aoki, Ayaka Kaku, Michihiko Iijima & Daiji Kambe

  2. Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan

    Shuji Yamamoto, Tsuyoshi Shibata, Kumi Abe, Taketoshi Okubo & Yoshinori Sekiguchi

  3. Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan

    Yasunori Kawakita

  4. Research Headquarters, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama, 331-9530, Japan

    Shigeru Okuyama

Authors
  1. Shigeyuki Chaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiharu Shimazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun-ichi Karasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ayaka Kaku
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michihiko Iijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daiji Kambe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuji Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasunori Kawakita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tsuyoshi Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kumi Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Taketoshi Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshinori Sekiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shigeru Okuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeyuki Chaki.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chaki, S., Shimazaki, T., Karasawa, Ji. et al. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia. Psychopharmacology 232, 2849–2861 (2015). https://doi.org/10.1007/s00213-015-3920-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-015-3920-3

Keywords

Search

Navigation